TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03458572

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Seirin Pyonex press needle acupuncture
Description: Acupuncture

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seirin Pyonex press needle acupuncture
Description: Acupuncture
Study: NCT01798329

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic VSL#3
Description: VSL#3 is a probiotic that reduces:~* urease faecal activity~* faecal pH~* inflammatory cytokine
Study: NCT00913484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Disulfiram 250 mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily
Study: NCT02961465

Intervention type: DEVICE
Intervention: Sacral Neuromodulation
Description: SNM starts with a screening phase. In this phase a tined lead is inserted into the third sacral foramen and attached to an external stimulator, after which the patient enters a four-week stimulation test period.~If the screening phase is successful (defecation frequency (DF) ≥3 a week), the external stimulator is changed for a pacemaker that is implanted in the buttocks. If the screening phase is unsuccessful (DF \<3 a week), the lead is explanted. Patients are asked to limit the use of additional conservative treatments for constipation (such as laxatives and colonic irrigation) to what is necessary to relieve (the most severe) complaints. What is necessary to relieve complaints is determined by the patient.
Study: NCT03049410

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intracorporeal Robot Assisted Radical Cystectomy
Description: Intracorporeal robot assisted radical cystoprostatectomy or anterior exenteration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Radical Cystectomy
Description: Removal of bladder and adjacent organs
Study: NCT04086420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Received instructions to exercise at moderate intensity while listening to an audio-recorded mindfulness-based physical activity intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Heart-Rate
Description: Given a heart rate monitor, told to exercise within the moderate intensity range (64-76% of estimated maximum heart rate)
Study: NCT03722134

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MOCA
Description: Great saphenous vein occlusion with a mechanochemical chateter which cause mechanical injury to vessel intima and gives sclerosant to the intima.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EVLA
Description: Great saphenous vein occlusion with a thermal laser chateter
Study: NCT02619604

Intervention type: OTHER
Group type: OTHER
Intervention: Education Intervention
Description: Education interventions will be delivered sporadically within the 6-month window between the time the clinician completes the pre-survey and when he/she completes the post-survey. Interventions consist of e-brief publications, teleconferences with project faculty, and evidence based resources.
Study: NCT00441584

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIntron (peginterferon alfa-2b)
Description: Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebetol (ribavirin)
Description: 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for up to 48 weeks
Study: NCT04521400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Interferon-beta 1a
Description: High dose IFN-β1a (Recigen) (Subcutaneous injections of 88μg (24,000 IU) on days 1, 3, 6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: Lopinavir/Ritonavir (Kaletra) \[IFN-β1a group\] (400mg/100 mg twice a day for 10 days
Study: NCT03722134

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFA
Description: Great saphenous vein occlusion with a thermal radiofrequency chateter
Study: NCT00127101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Dose escalation study starting with vorinostat 200 mg q.d. capsules (1 capsule daily) and rising up to vorinostat 400 mg q.d. capsules (1 capsule daily). Up to 6 months of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Dose escalation study starting with vorinostat 200 mg q.d. capsules (1 capsule daily) and rising up to vorinostat 400 mg q.d. capsules (1 capsule daily). Up to 6 months of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Dose escalation study starting with vorinostat 200 mg q.d. capsules (1 capsule daily) and rising up to vorinostat 400 mg q.d. capsules (1 capsule daily). Up to 6 months of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Dose escalation study starting with vorinostat 200 mg q.d. capsules (1 capsule daily) and rising up to vorinostat 400 mg q.d. capsules (1 capsule daily). Up to 6 months of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Dose escalation study starting with vorinostat 200 mg q.d. capsules (1 capsule daily) and rising up to vorinostat 400 mg q.d. capsules (1 capsule daily). Up to 6 months of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Dose escalation study starting with vorinostat 200 mg q.d. capsules (1 capsule daily) and rising up to vorinostat 400 mg q.d. capsules (1 capsule daily). Up to 6 months of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: bexarotene
Description: Dose escalation with bexarotene 150 mg/m2 capsules rising up to 300 mg/m2 capsules (1 capsule daily). Up to 6 months of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: bexarotene
Description: Dose escalation with bexarotene 150 mg/m2 capsules rising up to 300 mg/m2 capsules (1 capsule daily). Up to 6 months of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: bexarotene
Description: Dose escalation with bexarotene 150 mg/m2 capsules rising up to 300 mg/m2 capsules (1 capsule daily). Up to 6 months of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: bexarotene
Description: Dose escalation with bexarotene 150 mg/m2 capsules rising up to 300 mg/m2 capsules (1 capsule daily). Up to 6 months of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: bexarotene
Description: Dose escalation with bexarotene 150 mg/m2 capsules rising up to 300 mg/m2 capsules (1 capsule daily). Up to 6 months of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: bexarotene
Description: Dose escalation with bexarotene 150 mg/m2 capsules rising up to 300 mg/m2 capsules (1 capsule daily). Up to 6 months of treatment.
Study: NCT04262518

Intervention type: DEVICE
Group type: OTHER
Intervention: Outcomes4Me Mobile App
Description: A mobile app that provides patient navigation and treatment and clinical trial options to people with breast cancer
Study: NCT01830127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 24 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 high dose
Description: 24 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir
Description: 24 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 24 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 low dose
Description: 24 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir
Description: 24 Weeks
Study: NCT04092374

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Locking compression plates
Description: Fixation of sternal fracture using locking compression mechanism
Study: NCT03399695

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preoxygenation
Description: spontaneous breathing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preoxygenation
Description: spontaneous breathing
Study: NCT02382198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: Drug to reduce drooling in patients with Parkinson's Decease.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03097705

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: OCT (Optical coherence tomography)
Description: RNFL AND IOP MEASUREMNTS
Study: NCT03717896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200mg IV thiamine in 50mL 0.9% saline
Description: Thiamine 200mg IV every 12 hours for 2 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50mL 0.9% saline
Study: NCT04625725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7442
Description: * Single dose (× 2IM injections) of 300 mg of AZD7442 on parent study Day 1.~* Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 1.~* Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 183.~* Single dose (x 2IM injections) of 600mg of AZD7442 on sub-study Day 183 and Day 366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7442
Description: * Single dose (× 2IM injections) of 300 mg of AZD7442 on parent study Day 1.~* Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 1.~* Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 183.~* Single dose (x 2IM injections) of 600mg of AZD7442 on sub-study Day 183 and Day 366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7442
Description: * Single dose (× 2IM injections) of 300 mg of AZD7442 on parent study Day 1.~* Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 1.~* Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 183.~* Single dose (x 2IM injections) of 600mg of AZD7442 on sub-study Day 183 and Day 366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7442
Description: * Single dose (× 2IM injections) of 300 mg of AZD7442 on parent study Day 1.~* Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 1.~* Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 183.~* Single dose (x 2IM injections) of 600mg of AZD7442 on sub-study Day 183 and Day 366

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose (× 2IM injections) of saline placebo on parent study Day 1.
Study: NCT04538742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Tucatinib administered orally (tablet) twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Tucatinib administered orally (tablet) twice daily
Study: NCT05101239

Intervention type: DEVICE
Intervention: MRI imaging exam
Description: 3T MRI scan using with ultra high performance gradient subsystem (MAGNUS MRI)

Intervention type: DEVICE
Intervention: MRI imaging exam
Description: 3T MRI scan using with ultra high performance gradient subsystem (MAGNUS MRI)

Intervention type: DEVICE
Intervention: MRI imaging exam
Description: 3T MRI scan using with ultra high performance gradient subsystem (MAGNUS MRI)
Study: NCT02228265

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo blood and tissue collection

Intervention type: DRUG
Intervention: Enzalutamide
Description: Given PO

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03491761

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP Treatment
Description: PRP will be prepared using an Arthrex ACP® kit (a low-leukocyte Autologous Conditioned Plasma system). This is a single-spin system that concentrates platelets and separates red blood cells (RBCs) as well as white blood cells (WBCs) from the treatment product.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HA Treatment
Description: Euflexxa will be used for treatment. It will be prepared according to the package insert.
Study: NCT00313404

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Safety tested norovirus inoculum
Description: This is a safety tested live infectious norovirus inoculum that has been placed in groundwater that meets EPA drinking water standards
Study: NCT01208454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT04378348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview (MI)
Description: The MI dialogue will begin with an introduction where the LDL is asked about the type of work he does and his concerns regarding dangers in his workplace. This will be followed by a decisional balance exercise where the interviewer will engage the LDL in thinking about the pros and cons of taking jobs with many dangers and jobs with less dangers. Using a figure of a traffic light, the interviewer will proceed to measure how important it is for the LDL to reduce the dangers in his work place and identify his reasons for its importance. Next, the interviewer will measure the LDL's level of confidence in his ability to reduce the dangers in his workplace.Together, they will develop a plan to reduce the dangers in the workplace. Finally, the interviewer will summarize the safety plan to the LDL and will explain that the team will return to the corner in one month to see how the implementation of his plan went and to conduct a post-test survey

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory Group Activity
Description: Participants will view a figure of a pyramid representing the steps they can take to reduce the dangers in their workplace and the things that are in their control to reduce the dangers followed by pictures of dangerous work environments. They will be engaged in hazard identification and situational awareness by identifying and sharing out loud the dangers they see in the picture. Participants will also engage in problem solving by coming up with strategies they could use to reduce the dangers they identified in the picture and will measure their level of confidence in their ability to implement the strategies they have come up with, should they find themselves in a similar work situation. The group facilitator will summarize what the group has said and what they have learned during the group activity and will ask participants to voluntarily make a personal promise to take concrete steps to reduce the dangers at their work.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Condition
Description: At control corner sites, we will recruit another 35 Latino day laborer participants.Participants in the control group will receive OSHA pamphlets with standard workplace safety and health information. During our needs assessment survey, we collected information regarding workrelated injuries. Results from this survey indicate the following 4 categories are the highest cause of injury among surveyed Latino day laborers: 1) moving heavy objects, 2) falls, 3) being struck by falling or lying objects, and 4) serious cuts. The OSHA materials that will be distributed to participants will include safety and health information regarding these four topics. Furthermore, given that the LDL are continuously exposed to the sun (e.g., at the corner while waiting for work, at work, and on their way to and from work), heat exposure will also be included in the OSHA materials.
Study: NCT01894295

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corn oil pearl Capsules 1 gram; were given to the intervention group once a day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D analogue
Description: 1-α hydroxyvitamin D3 dose 0.25, 0.5 and 1 microgram were given to the intervention group once a day for 8 weeks
Study: NCT04750746

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Conventional Therapy Passive ROM and/or AROM exercises Muscle strengthening; Therapeutics stretching of the shoulder, the elbow, the wrist, and the fingers. Activities of daily living training, including eating, grooming, dressing, toileting, and transfer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Interventional therapy Xbox Kinect (Xbox 360, Microsoft,) For training, programs such as Boxing and Bowling in the Kinect sports pack and Rally Ball, 20,000 Leaks, and Space Pop in the Kinect adventure pack, all of which required the use of the upper extremities, will be selected
Study: NCT04184791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Each DBS electrode contact will be reprogrammed in 60hz and High Frequency Stimulation (180hz) in the Levodopa ON (medicated) and OFF (unmedicated) conditions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Each DBS electrode contact will be reprogrammed in 60hz and High Frequency Stimulation (180hz) in the Levodopa ON (medicated) and OFF (unmedicated) conditions.
Study: NCT01913418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suan-Zao-Ren Tang
Description: SZRT is composed of five herb ingredients as follows: Semen Zizyphi Spinosae (Suanzaoren), Sclerotium Poriae Cocos (Fuling), Radix Ligustici Chuanxiong (Chuanxiong), Rhizoma Anemarrhena (Zhimu), and Radix Glycyrrhizae (Gancao).The SZRT granules were packed in aluminum foil packages and administered orally at a dose of 4 g, three times per day for four weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Suan-Zao-Ren Tang placebo
Description: The Suan-Zao-Ren Tang placebo granules are prepared with 4 g starch inside the same colored and sized foil packages.
Study: NCT02644187

Intervention type: DEVICE
Group type: OTHER
Intervention: BF-RhodoLED
Description: Infrared light, with total dose of 37J/cm2.

Intervention type: DEVICE
Group type: OTHER
Intervention: BF-RhodoLED
Description: Infrared light, with total dose of 37J/cm2.

Intervention type: DEVICE
Group type: OTHER
Intervention: Aktilite CL128
Description: Infrared light, with total dose of 37J/cm2.

Intervention type: DEVICE
Group type: OTHER
Intervention: Aktilite CL128
Description: Infrared light, with total dose of 37J/cm2.

Intervention type: DRUG
Group type: OTHER
Intervention: BF200-ALA/5-aminolevulinic acid
Description: Prodrug applied to whole treatment area previous to illumination with either light source.

Intervention type: DRUG
Group type: OTHER
Intervention: BF200-ALA/5-aminolevulinic acid
Description: Prodrug applied to whole treatment area previous to illumination with either light source.

Intervention type: DRUG
Group type: OTHER
Intervention: BF200-ALA/5-aminolevulinic acid
Description: Prodrug applied to whole treatment area previous to illumination with either light source.

Intervention type: DRUG
Group type: OTHER
Intervention: BF200-ALA/5-aminolevulinic acid
Description: Prodrug applied to whole treatment area previous to illumination with either light source.
Study: NCT01639885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2b
Description: 1ug/kg (max 100ug) 7 days before and 22 days after first treatment with gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2b
Description: 1ug/kg (max 100ug) 7 days before and 22 days after first treatment with gemcitabine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: p53 SLP
Description: 8.2.3 The p53 SLP vaccine consists of 9 synthetic 25-30 amino acids long overlapping peptides, spanning amino acids 70-235 of the wt-p53 protein (patent number WO2008147186). Peptides are prepared at the GMP facility of the Department of Clinical Pharmacy and Toxicology of the LUMC. At the day of immunization peptides (0.3 mg/peptide) were dissolved in dimethyl sulfoxide (DMSO, final concentration 20%) admixed with 20 mM phosphate buffer (pH7.5) and emulsified with an equal volume of Montanide ISA-51.The vaccine (2.7mL) is administered subcutaneously.
Study: NCT03547089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viveve®
Description: A single treatment using Viveve® with 110 pulses administered to the vaginal introitus at 90 J/cm2
Study: NCT01421576

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High fat meal
Description: offer high fat-meal in the morning before drug intake.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High fat meal
Description: offer high fat-meal in the morning before drug intake.
Study: NCT03494387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: 80% versus 30% inspiratory oxygen concentration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: 80% versus 30% inspiratory oxygen concentration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antioxidants
Description: Antioxidants versus placebo